Literature DB >> 25780301

Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis.

Maria Kalafateli1, Christos Triantos1, Emmanuel Tsochatzis1, Marina Michalaki1, Efstratios Koutroumpakis1, Konstantinos Thomopoulos1, Venetsanea Kyriazopoulou1, Eleni Jelastopulu1, Andrew Burroughs1, Chryssoula Lambropoulou-Karatza1, Vasiliki Nikolopoulou1.   

Abstract

AIM: To investigate the adipokine levels of leptin, adiponectin, resistin, visfatin, retinol-binding protein 4 (RBP4), apelin in alcoholic liver cirrhosis (ALC).
METHODS: Forty non-diabetic ALC patients [median age: 59 years, males: 35 (87.5%), Child-Pugh (CP) score: median 7 (5-12), CP A/B/C: 18/10/12, Model for End-stage Liver Disease (MELD): median 10 (6-25), follow-up: median 32.5 mo (10-43)] were prospectively included. The serum adipokine levels were estimated in duplicate by ELISA. Somatometric characteristics were assessed with tetrapolar bioelectrical impedance analysis. Pearson's rank correlation coefficient was used to assess possible associations with adipokine levels. Univariate and multivariate Cox regression analysis was used to determine independent predictors for overall survival.
RESULTS: Body mass index: median 25.9 (range: 20.1-39.3), fat: 23.4% (7.6-42.1), fat mass: 17.8 (5.49-45.4), free fat mass: 56.1 (39.6-74.4), total body water (TBW): 40.6 (29.8-58.8). Leptin and visfatin levels were positively associated with fat mass (P < 0.001/P = 0.027, respectively) and RBP4 with TBW (P = 0.025). Median adiponectin levels were significantly higher in CPC compared to CPA (CPA: 7.99 ± 14.07, CPB: 7.66 ± 3.48, CPC: 25.73 ± 26.8, P = 0.04), whereas median RBP4 and apelin levels decreased across the spectrum of disease severity (P = 0.006/P = 0.034, respectively). Following adjustment for fat mass, visfatin and adiponectin levels were significantly increased from CPA to CPC (both P < 0.001), whereas an inverse correlation was observed for both RBP4 and apelin (both P < 0.001). In the multivariate Cox regression analysis, only MELD had an independent association with overall survival (HR = 1.53, 95%CI: 1.05-2.32; P = 0.029).
CONCLUSION: Adipokines are associated with deteriorating liver function in a complex manner in patients with alcoholic liver cirrhosis.

Entities:  

Keywords:  Adipokines; Adiponectin; Cirrhosis; Leptin; Resistin

Mesh:

Substances:

Year:  2015        PMID: 25780301      PMCID: PMC4356923          DOI: 10.3748/wjg.v21.i10.3020

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  53 in total

1.  Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis.

Authors:  R Testa; R Franceschini; E Giannini; A Cataldi; F Botta; A Fasoli; P Tenerelli; E Rolandi; T Barreca
Journal:  J Hepatol       Date:  2000-07       Impact factor: 25.083

2.  Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal.

Authors:  J H Henriksen; J J Holst; S Møller; K Brinch; F Bendtsen
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

3.  High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo.

Authors:  Frank Tacke; Torsten Wüstefeld; Rüdiger Horn; Tom Luedde; Annavarapu Srinivas Rao; Michael P Manns; Christian Trautwein; Georg Brabant
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

Review 4.  Obesity and alcoholic liver disease.

Authors:  Anna Mae Diehl
Journal:  Alcohol       Date:  2004-08       Impact factor: 2.405

5.  Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease.

Authors:  Paul Angulo; Laura M Alba; Lydia M Petrovic; Leon A Adams; Keith D Lindor; Michael D Jensen
Journal:  J Hepatol       Date:  2004-12       Impact factor: 25.083

6.  Role of resistin in diet-induced hepatic insulin resistance.

Authors:  Evan D Muse; Silvana Obici; Sanjay Bhanot; Brett P Monia; Robert A McKay; Michael W Rajala; Philipp E Scherer; Luciano Rossetti
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

7.  Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin.

Authors:  Yoshihiro Kamada; Shinji Tamura; Shinichi Kiso; Hitoshi Matsumoto; Yukiko Saji; Yuichi Yoshida; Koji Fukui; Norikazu Maeda; Hitoshi Nishizawa; Hiroyuki Nagaretani; Yoshihisa Okamoto; Shinji Kihara; Jun-Ichiro Miyagawa; Yasuhisa Shinomura; Tohru Funahashi; Yuji Matsuzawa
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

8.  Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics.

Authors:  Uwe J F Tietge; Klaus H W Böker; Michael P Manns; Matthias J Bahr
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-03-09       Impact factor: 4.310

9.  Gender-dependent alterations in serum leptin in alcoholic cirrhosis.

Authors:  A J McCullough; E Bugianesi; G Marchesini; S C Kalhan
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682

10.  Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study.

Authors:  Fusun F Bolukbas; Cengiz Bolukbas; Mehmet Horoz; Mahmut Gumus; Mehmet Erdogan; Fadile Zeyrek; Ali Yayla; Oya Ovunc
Journal:  BMC Gastroenterol       Date:  2004-09-23       Impact factor: 3.067

View more
  16 in total

1.  Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.

Authors:  Raika Jamali; Mohsen Razavizade; Abbas Arj; Mohammad Hossein Aarabi
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

Authors:  Sabrina Krautbauer; Lisa Rein-Fischboeck; Elisabeth M Haberl; Rebekka Pohl; Reiner Wiest; Christa Buechler
Journal:  Clin Exp Med       Date:  2017-07-25       Impact factor: 3.984

Review 3.  A review of the role of ethanol-induced adipose tissue dysfunction in alcohol-associated liver disease.

Authors:  Thiyagarajan Gopal; Weilun Ai; Carol A Casey; Terrence M Donohue; Viswanathan Saraswathi
Journal:  Alcohol Clin Exp Res       Date:  2021-09-23       Impact factor: 3.928

Review 4.  Nutritional assessment in cirrhotic patients with hepatic encephalopathy.

Authors:  Fernando Gomes Romeiro; Laís Augusti
Journal:  World J Hepatol       Date:  2015-12-28

Review 5.  Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations.

Authors:  Richard Parker; Seung-Jin Kim; Bin Gao
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 6.  Adipokines in Liver Cirrhosis.

Authors:  Christa Buechler; Elisabeth M Haberl; Lisa Rein-Fischboeck; Charalampos Aslanidis
Journal:  Int J Mol Sci       Date:  2017-06-29       Impact factor: 5.923

7.  Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis.

Authors:  Michał Kukla; Marek Waluga; Michał Żorniak; Agnieszka Berdowska; Piotr Wosiewicz; Tomasz Sawczyn; Rafał J Bułdak; Marek Ochman; Katarzyna Ziora; Tadeusz Krzemiński; Marek Hartleb
Journal:  World J Gastroenterol       Date:  2017-04-14       Impact factor: 5.742

8.  Sexual Dimorphism in Alcohol Induced Adipose Inflammation Relates to Liver Injury.

Authors:  Melissa A Fulham; Pranoti Mandrekar
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

9.  Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.

Authors:  Antonino Tuttolomondo; Domenico Di Raimondo; Chiara Bellia; Giuseppe Clemente; Rosaria Pecoraro; Carlo Maida; Irene Simonetta; Valerio Vassallo; Danilo Di Bona; Eliana Gulotta; Marcello Ciaccio; Antonio Pinto
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

Review 10.  Apelin/APJ system: A key therapeutic target for liver disease.

Authors:  Shuang-Yu Lv; Binbin Cui; Wei-Dong Chen; Yan-Dong Wang
Journal:  Oncotarget       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.